Disease Markers / 2018 / Article / Tab 3

Review Article

Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients

Table 3

Meta-analysis of the association between CEA or CA15-3 and clinicopathological features of breast cancer.

VariablesCEACA15-3
Number of studiesNumber of patientsOR (95% CI)PHeterogeneity I2 (%)Heterogeneity PhModeNumber of studiesNumber of patientsOR (95% CI)PHeterogeneity I2 (%)Heterogeneity PhMode

Age (≤35 versus >35)312100.52 (0.29–0.94)0.03100.33Fixed312511.83 (1.20–2.80)0.00500.87Fixed
Menopause (no versus yes)37920.75 (0.33–1.69)0.49620.07Random515241.16 (0.90–1.50)0.25190.29Fixed
Tumor size (≤5 cm versus >5 cm)513850.28 (0.13–0.57)<0.001690.01Random927660.42 (0.29–0.63)<0.001620.007Random
Lymph node metastasis (no versus yes)634970.44 (0.36–0.53)<0.001130.33Fixed948670.59 (0.38–0.93)0.0284<0.001Random
TNM stage (I-II versus III-IV)747060.39 (0.25–0.60)<0.001770.0002Random1052980.34 (0.20–0.58)<0.00188<0.001Random
Histological grade (I-II versus III)526930.87 (0.58–1.31)0.50530.07Random839800.63 (0.46–0.87)0.005640.006Random
ER (no versus yes)530470.75 (0.41–1.38)0.36810.0003Random841941.23 (0.93–1.61)0.14500.05Random
PR (no versus yes)326220.83 (0.47–1.46)0.52780.01Random738101.01 (0.86–1.18)0.9500.91Fixed
HER-2 (no versus yes)27300.67 (0.25–1.78)0.42830.01Random513051.11 (0.83–1.47)0.4800.76Fixed
Luminal type (no versus yes)312000.72 (0.37–1.39)0.33630.07Random413961.32 (0.77–2.22)0.31650.04Random
HER-2 overexpress type (no versus yes)312000.78 (0.32–1.89)0.57670.05Random413960.75 (0.50–1.14)0.18460.13Fixed
Triple-negative type (no versus yes)312002.08 (1.30–3.33)0.003520.12Fixed413960.91 (0.65–1.28)0.5900.51Fixed

OR: odds ratio; 95% CI: 95% confidence interval; Ph: values of Q for heterogeneity test; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor 2.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.